Why we invested in Subtle Medical’s $12.2 M Series A round

Subtle Medical is our fund’s first US investment. And we couldn’t have picked a better company for our first investment outside Europe.

Founded by Enhao Gong, PhD and Greg Zaharchuk, MD, PhD, Subtle Medical are a spin-out of Stanford university. The outstanding team bring vast clinical and deep learning expertise, underpinned by great entrepreneurial spirit and academic rigor. Earlier this year, Subtle Medical were named as one of the top 100 AI healthcare companies in the world by CB Insights.

In a few years since inception, Subtle Medical have had an impressive impact on the international radiology community, which is well known for its radiologists who are naturally cynical of the role of AI in their field. The team’s success is attributable to the fact that their unique, clinically validated technology meets a very specific clinical need. As radiology faces ever-increasing demand and a shortage of radiologists, Subtle’s technology is timely.

MRI scans often take a long time to acquire and there can be many ‘artefacts’ which cause image degradation. As a radiologist, our founder, Dr Fiona Pathiraja, understands first-hand the challenges that long scan times and scans interrupted with ‘artefacts’ can cause to patients, radiologists and hospital providers. We understand what a company truly needs to do improve the lives of radiologists and patients on a daily basis. Subtle Medical’s FDA-approved and CE-marked AI technology reduces scan acquisition time on both MRI and PET scans whilst providing improved and enhanced superior image quality. This, in turn, enables increased workflow productivity and better patient experience.

The series A funding will be used to grow Subtle’s portfolio of image enhancement technology and support increasing global demand. Subtle have created the industry’s first AI-powered software solutions for vendor-agnostic medical imaging enhancement on SubtleMR™ and SubtlePET™. The new financing will further boost Subtle’s robust product pipeline, which includes SubtleGAD™ for lowering gadolinium dose in contrast-enhanced MRI, and technologies
in image-guided therapies.

Subtle’s technology already has global reach, being trusted by hospitals across the world including the US, Europe, China and Canada. We are proud investors and are looking forward to supporting Enhao, Greg and the whole team as they build the future of radiology.

Learn more about Subtle Medical here.

We are

We're at the start of an exciting new chapter to shape the future of healthcare in new ways. Come back soon to visit our new website for details, or visit our current website in the meantime.

We are evolving, new site coming soon...